Aurinia Pharmaceuticals AUPH Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $34.36M-83.7% | $210.79M+568% | $31.55M+46.7% | $21.51M-7.8% | $23.34M+1,534% | ||
| $4.82M-1.0% | $4.86M0.0% | $4.87M0.0% | $4.86M+0.2% | $4.86M-0.1% | ||
| -$866K-113% | $6.73M+13.7% | $5.92M+8.8% | $5.44M+260% | -$3.41M-138% | ||
| $9.28M— | —— | —— | —— | $0— | ||
| $720K-19.7% | $897K— | —— | $308K-95.6% | $6.97M— | ||
| -$652K— | —— | -$1.1M-21.9% | -$901K+7.5% | -$974K— | ||
| -$5.59M— | —— | -$641K— | —— | -$23.41M-234% | ||
| -$581K-112% | $5.05M+802% | -$720K+60.2% | -$1.81M+22.3% | -$2.33M-309% | ||
| $1.08M— | —— | —— | $805K-81.5% | $4.34M-17.6% | ||
| -$950K+79.3% | -$4.58M— | —— | —— | -$6.03M— | ||
| -$214K-5.9% | -$202K+1.5% | -$205K-2.5% | -$200K-2.6% | -$195K+2.5% | ||
| $7.72M-28.0% | $10.73M+215% | -$9.36M— | $0-100% | $3.81M+6,139% | ||
| $32.56M-28.7% | $45.67M+2.7% | $44.45M+0.5% | $44.24M+3,303% | $1.3M-95.7% | ||
| -$18.08M+50.8% | -$36.76M— | —— | —— | $31.03M-20.9% | ||
| $36.17M— | $0-100% | $8.67M-79.6% | $42.56M-9.3% | $46.92M+115% | ||
| $713K+101% | $355K— | —— | —— | $9.29M+2,338% | ||
| $3.65M+4.8% | $3.49M+1.1% | $3.45M-44.4% | $6.2M+124% | $2.77M-8.5% | ||
| $14.58M+3,905% | $364K0.0% | $364K+253% | $103K-98.8% | $8.93M+3,591% | ||
| -$53.69M-2,742% | -$1.89M+82.0% | -$10.49M+76.4% | -$44.39M+10.0% | -$49.34M-114% | ||
| -$39.21M— | —— | —— | -$13.43M+21.0% | -$17.01M-137% | ||
| $1.33M— | $0-100% | $2.03M+147% | $820K+233% | $246K-66.1% | ||
| $2.32M-0.7% | $2.34M-11.0% | $2.63M+2.4% | $2.56M-3.5% | $2.66M-10.8% | ||
| $416K+213% | -$367K-592% | -$53K+99.3% | -$7.45M-311% | -$1.81M-135% | ||
| -$5.59M— | —— | -$641K— | —— | -$23.41M-234% | ||
| -$214K-5.9% | -$202K+1.5% | -$205K-2.5% | -$200K-2.6% | -$195K+2.5% | ||
| -$950K+79.3% | -$4.58M— | —— | —— | -$6.03M— | ||
| -$581K-112% | $5.05M+802% | -$720K+60.2% | -$1.81M+22.3% | -$2.33M-309% | ||
| $39K-45.8% | $72K+10.8% | $65K-33.7% | $98K+476% | $17K-69.6% | ||
| $3.65M+4.8% | $3.49M+1.1% | $3.45M-44.4% | $6.2M+124% | $2.77M-8.5% | ||
| $1.08M— | —— | —— | $805K-81.5% | $4.34M-17.6% | ||
| -$214K-5.9% | -$202K+1.5% | -$205K-2.5% | -$200K-2.6% | -$195K+2.5% | ||
| —— | $943.25K0.0% | $943.25K0.0% | $943.25K0.0% | $943.25K— | ||
| $1.33M— | $0-100% | $2.03M+147% | $820K+233% | $246K-66.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aurinia Pharmaceuticals generate?
- Aurinia Pharmaceuticals (AUPH) generated $166.9M in operating cash flow over the trailing twelve months.
- Where does Aurinia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
